Dr. Scott Rothbart (IMAGE)

Van Andel Research Institute

Dr. Scott Rothbart

Caption

A new preclinical study by Van Andel Institute Professor Dr. Scott Rothbart and colleagues reveals how two epigenetic cancer medications approved for separate uses may hold promise for treating colorectal cancers and other solid tumors. 

Credit

Courtesy of Van Andel Institute

Usage Restrictions

Please use attribution: Courtesy of Van Andel Institute

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.